Synonym
MDK-4204; MDK 4204; MDK4204; Anticancer AgentI; Anticancer Agent I; Anticancer Agent-I
IUPAC/Chemical Name
(3E,5E)-1-[[1-[(2-Fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-3,5-bis[(4-methylphenyl)methylene]-4-piperidinone
InChi Key
YHWZDCHFTZTNIV-DPCVLPDWSA-N
InChi Code
InChI=1S/C31H29FN4O/c1-22-7-11-24(12-8-22)15-27-17-35(18-28(31(27)37)16-25-13-9-23(2)10-14-25)20-29-21-36(34-33-29)19-26-5-3-4-6-30(26)32/h3-16,21H,17-20H2,1-2H3/b27-15+,28-16+
SMILES Code
O=C1/C(CN(CC2=CN(CC3=CC=CC=C3F)N=N2)C/C1=C\C4=CC=C(C)C=C4)=C/C5=CC=C(C)C=C5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
492.60
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Res. 2017 Mar;37(3):1523-1528. PubMed PMID: 28314328.
2: Arvanitis CD, Bazan-Peregrino M, Rifai B, Seymour LW, Coussios CC. Cavitation-enhanced extravasation for drug delivery. Ultrasound Med Biol. 2011 Nov;37(11):1838-52. doi: 10.1016/j.ultrasmedbio.2011.08.004. Epub 2011 Oct 2. PubMed PMID: 21963037.
3: Beck R, Dejeans N, Glorieux C, Pedrosa RC, Vásquez D, Valderrama JA, Calderon PB, Verrax J. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. Curr Med Chem. 2011;18(18):2816-25. Review. PubMed PMID: 21568884.
4: Ahn S, Kearbey JD, Li CM, Duke CB 3rd, Miller DD, Dalton JT. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos. 2011 Apr;39(4):636-43. doi: 10.1124/dmd.110.036673. Epub 2011 Jan 13. PubMed PMID: 21233217.
5: Marx G, Zhou H, Graves DE, Osheroff N. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Biochemistry. 1997 Dec 16;36(50):15884-91. PubMed PMID: 9398321.
